Journal Article

Epididymoorchitis Due to <i>Brucella mellitensis:</i> A Retrospective Study of 59 Patients

Amalia Navarro-Martïnez, Javier Solera, Juan Corredoira, José Luís Beato, Elisa Martínez Alfaro, Manuel Atiénzar and Javier Ariza

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 33, issue 12, pages 2017-2022
Published in print December 2001 | ISSN: 1058-4838
Published online December 2001 | e-ISSN: 1537-6591 | DOI:
Epididymoorchitis Due to Brucella mellitensis: A Retrospective Study of 59 Patients

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Epididymoorchitis is a focal form of human brucellosis described in 2%–20% of patients with brucellosis. We assessed 59 cases of Brucella epididymoorchitis (BEO) between 1991 and 1999. The median age of patients was 34 years (range, 15–75 years). The onset of symptoms was acute in 46 patients (78%). Scrotal pain and swelling (100% of patients), fever (88%), and sweating (73%) were the most common symptoms. Brucella species was isolated from blood cultures in 41 patients (69%) and from epididymal aspiration in 4 patients. Treatment consisted of a combination of a doxycycline and an aminoglycoside (n = 39) or rifampin (n = 10); trimethoprim-sulfamethoxazole with rifampin (n = 3); or trimethoprim-sulfamethoxazole as monotherapy (n = 7). The median duration of therapy was 45 days (range, 21–90 days). The infections of 9 patients (15%) failed to respond to therapy, and 15 patients relapsed (25%). Three patients with necrotizing orchitis whose infections were unresponsive to antibiotics required an orchiectomy. In general, classical brucellosis therapy is adequate for BEO.

Journal Article.  3990 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.